in conjunction with its academic partner, the Institute of Molecular Biosciences of Leopold Franzens University in Graz, Austria and its corporate partner, Sanochemia Pharmazeutika AG, based in Vienna and having research laboratories and manufacturing facilities in Neufeld, Austria, is engaged in the development of novel diagnostic and therapeutic oncological approaches. 
Furthest along is , its trademarked  bladder cancer diagnostic with phase IIb clinical studies having been completed, and indications of therapeutic effects having been shown in vitro. 
International Patents for Newfieldâ€™s anti cancer peptides have recently been issued and apply to a broad range of solid tumors, exploiting the interaction between human lactoferricin derivatives and phosphatidylserine, expressed on the outside of cancerous cells. In order to advance from the preclinical stage to clinical studies is entertaining academic and corporate partnerships.  
